Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CFB | P00751 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929296 | 0.95 | GAA (0.35) | GAAKMT2ACFBTSHRNPSR1 | |
| SCHEMBL5929363 | 0.91 | KMT2A (0.39) | GAAKMT2ACFBALDH1A1KDM4E | |
| SCHEMBL5929141 | 0.90 | KMT2A (0.38) | GAAKMT2ACFBHSD11B1ALDH1A1 | |
| SCHEMBL5929038 | 0.88 | DRD2 (0.40) | GAAKMT2ACFBTSHRALDH1A1 | |
| SCHEMBL5928984 | 0.88 | ALDH1A1 (0.41) | GAAKMT2ACFBALDH1A1KDM4E | |
| SCHEMBL5929078 | 0.87 | KCNK3 (0.37) | GAAKMT2ACFBTSHRALDH1A1 | |
| SCHEMBL5929122 | 0.87 | KMT2A (0.41) | GAAKMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL5929090 | 0.87 | KDM4E (0.38) | GAAKMT2ACFBALDH1A1KDM4E | |
| SCHEMBL5928924 | 0.86 | KMT2A (0.37) | GAAKMT2ACFBNPSR1ALDH1A1 | |
| SCHEMBL5929174 | 0.86 | CFB (0.37) | GAAKMT2ACFBNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | GAA 4885/4885KMT2A 2955/4885CFB 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.